Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.925 EUR | +1.29% | +3.29% | -21.50% |
Apr. 03 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
2023 | Valbiotis: capital increase successfully completed | CF |
Sales 2023 * | 6.17M 6.6M | Sales 2024 * | 8.4M 8.99M | Capitalization | 61.91M 66.26M |
---|---|---|---|---|---|
Net income 2023 * | -10M -10.7M | Net income 2024 * | -10M -10.7M | EV / Sales 2023 * | 6.82 x |
Net cash position 2023 * | 19.83M 21.23M | Net cash position 2024 * | 17.13M 18.34M | EV / Sales 2024 * | 5.33 x |
P/E ratio 2023 * |
-4.2
x | P/E ratio 2024 * |
-4.56
x | Employees | 48 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 91.48% |
1 day | +1.29% | ||
1 week | +3.29% | ||
Current month | +8.13% | ||
1 month | +9.03% | ||
3 months | -10.80% | ||
6 months | -29.66% | ||
Current year | -21.50% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | - | |
Frédéric Pelong
DFI | Director of Finance/CFO | 50 | 22-06-29 |
Jean Zetlaoui
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Agnès Tixier
BRD | Director/Board Member | - | 19-03-17 |
Laurent Lévy
CHM | Chairman | 53 | 17-02-28 |
Chief Executive Officer | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 3.925 | +1.29% | 54,196 |
24-04-22 | 3.875 | +0.26% | 9,725 |
24-04-19 | 3.865 | -0.51% | 8,045 |
24-04-18 | 3.885 | +1.17% | 21,143 |
24-04-17 | 3.84 | +1.05% | 8,391 |
Real-time Euronext Paris, April 23, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.50% | 66.24M | |
-0.49% | 105B | |
+3.31% | 97.5B | |
+1.66% | 22.19B | |
-16.16% | 21.33B | |
-6.82% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- ALVAL Stock